Effect of Vitamin D on Everolimus Trough Concentrations Among Heart Transplanted Patients
- Conditions
- Vitamin D Deficiency
- Registration Number
- NCT03403647
- Lead Sponsor
- Sheba Medical Center
- Brief Summary
Vitamin D is part of the regular treatment regimen among patients after heart transplantation. Due to potential drug-drug interaction between vitamin D and everolmus, these patients are in increased risk for increased everolimus metabolism, potentially leading to under- immunosupression.
- Detailed Description
post heart transplantation patients treated with everolimus will be screened for vitamin D levels. Patients defined as deficient will be treated with vitamin D with close and intensive monitoring everolimus levels, adjusting oral daily dose to maintain therapeutic levels.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Heart transplanted patients treated with everolimus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Oral daily everolimus dose change 8 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Sheba Medical Center🇮🇱Ramat Gan, Israel